Mar 27, 2018
Pacific Biosciences Announces Ten-Unit Sequel System Order for Annoroad

MENLO PARK, Calif., March 27, 2018 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (Nasdaq:PACB), the leader in long-read, high-resolution sequencing, today announced a purchase order for 10 PacBio® Sequel® Systems that are expected to be installed at Annoroad’s designated facility within the next several months, enhancing Annoroad’s large-scale genomic service capabilities across various fields within the life sciences such as agriculture, basic research, medicine, and health.

The Sequel System, based on Pacific Biosciences’ unique Single Molecule, Real-Time (SMRT®) technology, provides an unmatched depth of genetic information through exceptionally long sequencing reads, uniform coverage, and the highest consensus accuracy available today. The technology allows scientists to go beyond fragmented draft genomes and generate the most comprehensive de novo assemblies.

“SMRT Sequencing has demonstrated great value in many applications.  The collaboration between Annoroad and PacBio will further enhance Annoroad’s strategic maneuver and greatly augment our competitiveness,” said Dawei Li, President of Annoroad.

Dr. Michael Hunkapiller, Chairman and CEO of Pacific Biosciences added: “We are excited that Annoroad, one of the leading service providers in China, has decided to acquire the latest generation of PacBio systems. By adopting our Sequel platform, Annoroad shows confidence in integrating SMRT Sequencing into its wide array of service offerings in which long reads based on SMRT technology have become instrumental. We are confident that the Sequel Systems will be an important contributor to many initiatives, such as the ATCG (Annoroad Typical Chinese Genomes) Database announced in 2017 and Annoroad’s ambition to become a bigger player on the world stage. We are particularly pleased that Annoroad chose this significant investment in our SMRT Sequencing technology even after careful evaluation of alternatives.”

About Pacific Biosciences
Pacific Biosciences of California, Inc. (NASDAQ:PACB) offers sequencing systems to help scientists resolve genetically complex problems. Based on its novel Single Molecule, Real-Time (SMRT®) technology, Pacific Biosciences’ products enable: de novo genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms in important gene families, and find novel genes; targeted sequencing to more comprehensively characterize genetic variations; and real-time kinetic information for epigenome characterization. Pacific Biosciences’ technology provides high accuracy, ultra-long reads, uniform coverage, and the ability to simultaneously detect epigenetic changes. PacBio® sequencing systems, including consumables and software, provide a simple, fast, end-to-end workflow for SMRT Sequencing. More information is available at www.pacb.com.

About Annoroad
Annoroad is headquartered in Beijing and is a well-known enterprise in the genomic industry in China. The company is committed to providing cutting-edge genomic solutions in both clinical testing and life science research. Annoroad was given the distinction of “National High Innovative Technology Enterprise,” and chartered as the national clinical pilot site of NGS in China given its major position in the domestic market and next-gen sequencing technology.  Annoroad has developed a series of NGS diagnostic applications in the field of human reproduction, cancer, and rare diseases, forming an excellent product line and brand recognition. In the field of science and technology service, Annoroad provides state-of-the-art sequencing and bioinformatics solutions for research organizations. More information is available at http://en.annoroad.com/.

Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to purchase commitments, future installations, availability, uses, quality or performance of, or benefits of using, products or technologies, and other future events. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, changes in circumstances and other factors that are, in some cases, beyond Pacific Biosciences’ control and could cause actual results to differ materially from the information expressed or implied by forward-looking statements made in this press release. Factors that could materially affect actual results can be found in Pacific Biosciences’ most recent filings with the Securities and Exchange Commission, including Pacific Biosciences’ most recent reports on Forms 8-K, 10-K and 10-Q, and include those listed under the caption “Risk Factors.”

Pacific Biosciences undertakes no obligation to revise or update information in this press release to reflect events or circumstances in the future, even if new information becomes available.

Contacts

Media:
Nicole Litchfield
415.793.6468
nicole@bioscribe.com

Investors:
Trevin Rard
650.521.8450
ir@pacificbiosciences.com

Primary Logo

Source: Pacific Biosciences, Inc.

STOCK QUOTE

Copyright Nasdaq. Minimum 15 minutes delayed.

Investor
Contact

Pacific Biosciences

1305 O’Brien Drive

Menlo Park, CA  94025

ir@pacb.com